Literature DB >> 16081683

Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy.

Irma Airoldi1, Emma Di Carlo, Claudia Cocco, Carlo Sorrentino, Franco Fais, Michele Cilli, Tommaso D'Antuono, Mario Paolo Colombo, Mario Paulo Colombo, Vito Pistoia.   

Abstract

The interleukin-12 receptor beta2 (Il12rb2) gene is silenced in tumor cells from different human B-cell malignancies as opposed to their normal counterparts. It was hypothesized that this silencing allows neoplastic B cells to escape the control exerted by IL-12 on their growth. The aim of this study was to investigate whether targeted inactivation of the Il12rb2 gene in mice resulted into increased susceptibility to spontaneous tumor formation and immunopathology. Il12rb2 gene-deficient animals developed in the first year of life immune-complex mesangial glomerulonephritis with serum antinuclear antibodies. In older animals, multiorgan lymphoid infiltrates with features of vasculitis and Sjögren syndrome were detected in association with systemic B- and T-cell activation. In half of aged animals, lymph node plasmacytoma or lung carcinoma was observed. A mechanism for spontaneous development of autoimmune pathology and B-cell tumors is suggested by a strong IL-6 up-regulation detected in splenocytes and lymphoid infiltrates associated with oligoclonal B-cell expansion. The emergence of lung tumors may likely be attributed to an interferon-gamma (IFN-gamma) deficiency secondary to lack of IL-12 signaling. The development of autoimmunity, lymphoproliferation, and B-cell tumors in Il12rb2 knockout (KO) mice suggests that IL-12 functions physiologically to restrain aberrant B-cell activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081683     DOI: 10.1182/blood-2005-05-2034

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations.

Authors:  Lara Bossini-Castillo; Jose-Ezequiel Martin; Jasper Broen; Olga Gorlova; Carmen P Simeón; Lorenzo Beretta; Madelon C Vonk; Jose Luis Callejas; Ivan Castellví; Patricia Carreira; Francisco José García-Hernández; Mónica Fernández Castro; Marieke J H Coenen; Gabriela Riemekasten; Torsten Witte; Nicolas Hunzelmann; Alexander Kreuter; Jörg H W Distler; Bobby P Koeleman; Alexandre E Voskuyl; Annemie J Schuerwegh; Øyvind Palm; Roger Hesselstrand; Annika Nordin; Paolo Airó; Claudio Lunardi; Raffaella Scorza; Paul Shiels; Jacob M van Laar; Ariane Herrick; Jane Worthington; Christopher Denton; Filemon K Tan; Frank C Arnett; Sandeep K Agarwal; Shervin Assassi; Carmen Fonseca; Maureen D Mayes; Timothy R D J Radstake; Javier Martin
Journal:  Hum Mol Genet       Date:  2011-11-10       Impact factor: 6.150

Review 2.  Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Authors:  Juming Yan; Mark J Smyth; Michele W L Teng
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

3.  NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome.

Authors:  Sylvie Rusakiewicz; Gaetane Nocturne; Thierry Lazure; Michaela Semeraro; Caroline Flament; Sophie Caillat-Zucman; Damien Sène; Nicolas Delahaye; Eric Vivier; Kariman Chaba; Vichnou Poirier-Colame; Gunnel Nordmark; Maija-Leena Eloranta; Per Eriksson; Elke Theander; Helena Forsblad-d'Elia; Roald Omdal; Marie Wahren-Herlenius; Roland Jonsson; Lars Rönnblom; Joanne Nititham; Kimberly E Taylor; Christopher J Lessard; Kathy L Moser Sivils; Jacques-Eric Gottenberg; Lindsey A Criswell; Corinne Miceli-Richard; Laurence Zitvogel; Xavier Mariette
Journal:  Sci Transl Med       Date:  2013-07-24       Impact factor: 17.956

Review 4.  Cutting-edge issues in primary biliary cirrhosis.

Authors:  Marco Folci; Francesca Meda; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

5.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Authors:  Jacqueline M Benson; Clifford W Sachs; George Treacy; Honghui Zhou; Charles E Pendley; Carrie M Brodmerkel; Gopi Shankar; Mary A Mascelli
Journal:  Nat Biotechnol       Date:  2011-07       Impact factor: 54.908

Review 6.  IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.

Authors:  Michele W L Teng; Edward P Bowman; Joshua J McElwee; Mark J Smyth; Jean-Laurent Casanova; Andrea M Cooper; Daniel J Cua
Journal:  Nat Med       Date:  2015-06-29       Impact factor: 53.440

Review 7.  IL-35 and Autoimmunity: a Comprehensive Perspective.

Authors:  Jinjung Choi; Patrick S C Leung; Christopher Bowlus; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

8.  Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.

Authors:  Samantha K Greaney; Alain P Algazi; Katy K Tsai; Kathryn T Takamura; Lawrence Chen; Christopher G Twitty; Li Zhang; Alan Paciorek; Robert H Pierce; Mai H Le; Adil I Daud; Lawrence Fong
Journal:  Cancer Immunol Res       Date:  2019-12-18       Impact factor: 11.151

Review 9.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions.

Authors:  Irma Airoldi; Emma Di Carlo; Claudia Cocco; Emanuela Caci; Michele Cilli; Carlo Sorrentino; Gabriella Sozzi; Silvano Ferrini; Sandra Rosini; Giulia Bertolini; Mauro Truini; Francesco Grossi; Luis Juan Vicente Galietta; Domenico Ribatti; Vito Pistoia
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.